Statins and bone morphogenetic proteins: New pathways in bone formation

Annals of the Academy of Medicine Singapore

Volumn 31, Issue 2, 2002, Pages 245-247

  Edwards, Christoper J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Bone mineral density; Cholesterol; Fracture; Osteoporosis

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CHOLESTEROL; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

BONE DENSITY; BONE METABOLISM; BONE MINERAL; CHOLESTEROL SYNTHESIS; FRACTURE; INFLAMMATION; META ANALYSIS; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW;

EID: 0036098872     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study
2. Stimulation of bone formation in vitro and in rodents by statins
3. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
4. Oral statins and increased bone-mineral density in postmenopausal women
5. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
6. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
7. HMG-CoA reductase inhibitors and the risk of fractures
8. Use of statins and risk of fractures
9. Statin use and fracture: A meta-analysis of 8 observational studies
10. Bisphosphonates: From the laboratory to the clinic and back again
11. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
12. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
13. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
14. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
15. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells
16. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
17. Long-term effects of pravastatin on plasma concentration of C-reactive protein